117 related articles for article (PubMed ID: 25778313)
1. miR-150 is a factor of survival in prostate cancer patients.
Dezhong L; Xiaoyi Z; Xianlian L; Hongyan Z; Guohua Z; Bo S; Shenglei Z; Lian Z
J BUON; 2015; 20(1):173-9. PubMed ID: 25778313
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
Kristensen H; Haldrup C; Strand S; Mundbjerg K; Mortensen MM; Thorsen K; Ostenfeld MS; Wild PJ; Arsov C; Goering W; Visakorpi T; Egevad L; Lindberg J; Grönberg H; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Clin Cancer Res; 2014 Apr; 20(8):2169-81. PubMed ID: 24737792
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of microRNA-93 downregulation in human colon cancer.
Xiao ZG; Deng ZS; Zhang YD; Zhang Y; Huang ZC
Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):296-301. PubMed ID: 23354160
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.
Yang J; Liu H; Wang H; Sun Y
Pathol Res Pract; 2013 Aug; 209(8):490-4. PubMed ID: 23827213
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma.
Fan Y; Fan J; Huang L; Ye M; Huang Z; Wang Y; Li Q; Huang J
Int J Clin Exp Pathol; 2015; 8(4):4132-7. PubMed ID: 26097603
[TBL] [Abstract][Full Text] [Related]
9. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Pichler M; Gerger A; Kapp KS; Langsenlehner T
Eur J Cancer; 2015 Mar; 51(5):610-9. PubMed ID: 25618827
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
11. Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients.
Ota D; Mimori K; Yokobori T; Iwatsuki M; Kataoka A; Masuda N; Ishii H; Ohno S; Mori M
Int J Oncol; 2011 Apr; 38(4):955-62. PubMed ID: 21271219
[TBL] [Abstract][Full Text] [Related]
12. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
[TBL] [Abstract][Full Text] [Related]
13. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
[TBL] [Abstract][Full Text] [Related]
14. Metastasis-related miR-185 is a potential prognostic biomarker for hepatocellular carcinoma in early stage.
Zhi Q; Zhu J; Guo X; He S; Xue X; Zhou J; Hu B; Li H; Chen S; Zhao H; Kuang Y
Biomed Pharmacother; 2013 Jun; 67(5):393-8. PubMed ID: 23648054
[TBL] [Abstract][Full Text] [Related]
15. Contrasting expression patterns of histone mRNA and microRNA 760 in patients with gastric cancer.
Iwaya T; Fukagawa T; Suzuki Y; Takahashi Y; Sawada G; Ishibashi M; Kurashige J; Sudo T; Tanaka F; Shibata K; Endo F; Katagiri H; Ishida K; Kume K; Nishizuka S; Iinuma H; Wakabayashi G; Mori M; Sasako M; Mimori K
Clin Cancer Res; 2013 Dec; 19(23):6438-49. PubMed ID: 24097871
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer.
Hulf T; Sibbritt T; Wiklund ED; Patterson K; Song JZ; Stirzaker C; Qu W; Nair S; Horvath LG; Armstrong NJ; Kench JG; Sutherland RL; Clark SJ
Oncogene; 2013 Jun; 32(23):2891-9. PubMed ID: 22869146
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer.
Inoue T; Iinuma H; Ogawa E; Inaba T; Fukushima R
Oncol Rep; 2012 Jun; 27(6):1759-64. PubMed ID: 22407237
[TBL] [Abstract][Full Text] [Related]
18. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
[TBL] [Abstract][Full Text] [Related]
19. CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.
Voutsadakis IA; Vlachostergios PJ; Daliani DD; Karasavvidou F; Kakkas G; Moutzouris G; Melekos MD; Papandreou CN
Urol Int; 2012; 88(2):158-64. PubMed ID: 22286396
[TBL] [Abstract][Full Text] [Related]
20. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer.
Chan JK; Kiet TK; Blansit K; Ramasubbaiah R; Hilton JF; Kapp DS; Matei D
Gynecol Oncol; 2014 Jun; 133(3):568-74. PubMed ID: 24680769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
